BOSTON ( TheStreet) -- Dr. Finny Kuruvilla, manager of the Eventide Gilead Fund ( ETGLX), says he's finding strong prospects among health care stocks, such as Momenta Pharmaceuticals ( MNTA) and Genoptix ( GXDX).
Analysts are most critical about Teva's plan to cut $5 billion in debt by the end of the year.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.